Hospitalization rates differ by hepatitis C status in an urban HIV cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 2, 2003, Pages 165-173

  Gebo, Kelly A ^a   Diener West, Marie ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis C; Highly active antiretroviral therapy; HIV; Hospitalization; Injection drug use

Indexed keywords

ANALGESIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ABSCESS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CELLULITIS; COHORT ANALYSIS; DRUG ABUSE; DRUG INTOXICATION; ETHNOLOGY; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; URBAN POPULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 0141923768     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200310010-00006     Document Type: Article

References (38)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Paul S, Gilbert HM, Ziecheck W, et al. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS. 1999;13:415-418.
3. Mocroft A, Barry S, Sabin CA, et al. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS. 1999;13:1255-1261.
4. Baum SE, Morris JT, Gibbons RV, et al. Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Mil Med. 1999;164:609-612.
5. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11(Suppl):F101-F105.
6. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med. 1997;336:1531-1532.
7. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
8. Quan CM, Krajden M, Grigoriew GA, et al. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1993;17:117-119.
9. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. 1997;350:1425-1431.
10. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:143-152.
11. Martin-Carbonero L, Soriano V, Valencia E, et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 2001;17:1467-1471.
12. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, et al. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis. 2001;33:1793-1795.
13. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;36:363-367.
14. Sande MA, Volberding PA. The Medical Management of AIDS. Philadelphia: WB Saunders; 1999:577.
15. Liang KY, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;986:13-22.
16. Soriano V, Garcia-Samaniego J, Valencia E, et al. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol. 1999;15:14.
17. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
18. Sulkowski MS, Mast EE, Seeff LB, et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(Suppl 1):S77-S84.
19. Solomon L, Stein M, Flynn C, et al. Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:253-261.
20. Solomon L, Frank R, Vlahov D, et al. Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. Am J Public Health. 1991;81:1285-1290.
21. Stein MD, O'Sullivan PS, Ellis P, et al. Utilization of medical services by drug abusers in detoxification. J Subst Abuse. 1993;5:187-193.
22. Mor V, Fleishman JA, Dresser M, et al. Variation in health service use among HIV-infected patients. Med Care. 1992;30:17-29.
23. Weber AE, Yip B, O'Shaughnessy MV, et al. Determinants of hospital admission among HIV-positive people in British Columbia. CMAJ. 2000;162:783-786.
24. Piette JD, Mor V, Mayer K, et al. The effects of immune status and race on health service use among people with HIV disease. Am J Public Health. 1993;83:510-514.
25. Fleishmann JA, Mor V, Laliberte LL. Longitudinal patterns of medical service use and costs among people with AIDS. Health Serv Res. 1995;30:403-424.
26. HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr. 2002;30(1):21-26.
27. Fleishmann JA, Hellinger FJ. Trends in HIV-related inpatient admissions from 1993 to 1997: a seven-state study. J Acquir Immune Defic Syndr. 2001;28:73-80.
28. Crystal S, Lo Sasso AT, Sambamoorthi U. Incidence and duration of hospitalizations among persons with AIDS: an event history approach. Health Serv Res. 1999;33:1611-1638.
29. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
30. Inoue A, Tsukuma H, Oshima A, et al. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis. J Epidemiol. 2000;10:234-240.
31. Aizawa Y, Shibamoto Y, Takagi I, et al. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer. 2000;89:53-59.
32. Benvegnu L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology. 1997;25:211-215.
33. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27:201-205.
34. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357:196-197.
35. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis. 1996;23:585-591.
36. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-456.
37. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore). 1995;74:212-220.
38. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655-661.